(Q37183252)

18 August 2017

1 reference

title

Chemotherapy for recurrent and metastatic cervical cancer (English)

1 reference

18 August 2017

1 reference

cervix uterine cancer

1 reference

3

Pedro T Ramirez

1 reference

18 August 2017

Xia Tao

1

1 reference

18 August 2017

Wei Hu

series ordinal

2

1 reference

18 August 2017

John J Kavanagh

series ordinal

4

1 reference

18 August 2017

language of work or name

English

0 references

publication date

3 June 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

110

1 reference

18 August 2017

issue

3 Suppl 2

1 reference

18 August 2017

page(s)

S67-71

1 reference

18 August 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

HPV vaccine fights cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

The role of chemotherapy in the management of carcinoma of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Management of metastatic cervical cancer: review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Phase II trial of carboplatin or iproplatin in cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups: a population based study with review of all nonsquamous cervical carcinomas in Norway from 1966 to 1970, 1976 to 1980,

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Small cell carcinoma of the female genital tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Clinicopathologic features of rhabdomyosarcoma of gynecologic origin in adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Glassy cell carcinoma of the uterine cervix: combination chemotherapy with paclitaxel and carboplatin in recurrent tumor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

HER2 expression in cervical cancer as a potential therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.024

10.1016/J.YGYNO.2008.04.024

7 January 2021

Identifiers

DOI

1 reference

18 August 2017

1 reference